On the stock market since 2021, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Sales run at $18.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 37 buys and 20 sells. Management buying with its own money is usually read as a good sign.
A loss of $64.8M against $18.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AHPA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AHPA is a high-risk stock — not yet profitable, and its future rides on its product catching on.